As of September 30, 2024, Inari Medical, Inc. has 58.44M shares outstanding.
| Shares Outstanding | 58.44M |
These figures are as of September 30, 2024. The price-to-sales ratio is 4.17, and the price-to-book ratio stands at -19.60.
| PS Ratio | 4.17 |
| PB Ratio | -19.60 |
| P/TBV Ratio | 30.90 |
| P/FCF Ratio | 104.33 |
| P/OCF Ratio | 169.14 |
These figures are as of September 30, 2024. The EV/Sales ratio of 4.04 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Inari Medical, Inc. trades at an EV/FCF ratio of 98.98, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.
| EV / Sales | 4.04 |
| EV / FCF | 98.98 |
As of September 30, 2024, Inari Medical, Inc. maintains a current ratio of 1.77, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 7.53, indicating elevated leverage, while an interest coverage ratio of -71.35 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.77 |
| Quick Ratio | 1.32 |
| Debt / Equity | 7.53 |
| Debt / EBITDA | -1.52 |
| Interest Coverage | -71.35 |
These figures cover the twelve months ended September 30, 2024. Return on assets (ROA) is negative at -12.61, reflecting losses generated across the asset base. Inventory turnover of 1.59 indicates how many times Inari Medical, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Assets (ROA) | -12.61 |
| Inventory Turnover | 1.59 |
Over the twelve months ended September 30, 2024, Inari Medical, Inc. posted a gross margin of 86.82, reflecting its pricing power and cost economics. The operating margin of -6.92 and net profit margin of -13.68 provide insight into operational efficiency.
| Gross Margin | 86.82 |
| Operating Margin | -6.92 |
| Pretax Margin | -9.29 |
| Profit Margin | -13.68 |
| EBITDA Margin | -3.75 |
These figures cover the twelve months ended September 30, 2024. Free cash flow yield stands at 0.96, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 0.07, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Inari Medical, Inc. shareholders.
| Shareholder Yield | 0.07 |
| FCF Yield | 0.96 |
As of September 30, 2024, Inari Medical, Inc. has an Altman Z-Score of 6.69, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 6.69 |